GlassScriptPhysician profile
Donna J Gamache
NPI 1063401446
$7,106.20
in general payments reported to CMS, 2019-2025
33 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $895 · 2020: $1,010 · 2021: $2,007 · 2022: $1,363 · 2023: $862 · 2024: $479 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,831.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $973.82 | 2019-2024 | Arexvy, Trelegy Ellipta |
| Abbvie INC. | $758.46 | 2020-2025 | |
| Novo Nordisk INC | $678.70 | 2019-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $606.17 | 2020-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $549.44 | 2019-2025 | |
| Astellas Pharma US INC | $430.51 | 2019-2024 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $415.15 | 2019-2024 | Eliquis |
| Janssen Pharmaceuticals, INC | $384.87 | 2019-2022 | |
| Esperion Therapeutics, INC. | $358.03 | 2021-2022 | |
| Lilly USA, LLC | $325.34 | 2019-2024 | Mounjaro, Zepbound, Trulicity |
| Allergan, INC. | $249.78 | 2019-2020 | |
| Amarin Pharma, INC. | $226.29 | 2019-2022 | |
| Amgen INC. | $159.47 | 2019-2024 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $137.67 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $125.00 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $118.77 | 2021-2025 | Freestyle Libre 3 |
| Novartis Pharmaceuticals Corporation | $107.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.55 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $68.85 | 2021 | |
| Lifescan, INC. | $36.69 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $36.30 | 2024 | |
| Valeritas, INC. | $31.71 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.13 | 2019-2021 | |
| Boston Scientific Corporation | $28.80 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $28.75 | 2020-2021 | |
| Eisai INC. | $23.31 | 2020 | |
| Vanda Pharmaceuticals INC. | $22.89 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $19.70 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.01 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.93 | 2023 | Qelbree |
| Kowa Pharmaceuticals America, INC. | $15.52 | 2021 | |
| Acadia Pharmaceuticals INC | $15.47 | 2025 | Daybue |
| Vistapharm, INC. | $15.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Gamache listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.